AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer

Purpose: Despite the use of 5-fluorouracil (5-FU)–based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse. Thus, novel therapeutic strategies are needed for early-stage colorectal cancer. Residual micrometastatic disease from the primary tumor is a major cause of patient relapse. Experimental Design: To model colorectal cancer tumor cell invasion/metastasis, we have generated invasive (KRASMT/KRASWT/+chr3/p53-null) colorectal cancer cell subpopulations. Receptor tyrosine kinase (RTK) screens were used to identify novel proteins that underpin the migratory/invasive phenotype. Migration/invasion was assessed using the XCELLigence system. Tumors from patients with early-stage colorectal cancer (N = 336) were examined for AXL expression. Results: Invasive colorectal cancer cell subpopulations showed a transition from an epithelial-to-mesenchymal like phenotype with significant increases in migration, invasion, colony-forming ability, and an attenuation of EGF receptor (EGFR)/HER2 autocrine signaling. RTK arrays showed significant increases in AXL levels in all invasive sublines. Importantly, 5-FU treatment resulted in significantly increased migration and invasion, and targeting AXL using pharmacologic inhibition or RNA interference (RNAi) approaches suppressed basal and 5-FU–induced migration and invasion. Significantly, high AXL mRNA and protein expression were found to be associated with poor overall survival in early-stage colorectal cancer tissues. Conclusions: We have identified AXL as a poor prognostic marker and important mediator of cell migration/invasiveness in colorectal cancer. These findings provide support for the further investigation of AXL as a novel prognostic biomarker and therapeutic target in colorectal cancer, in particular in the adjuvant disease in which EGFR/VEGF–targeted therapies have failed. Clin Cancer Res; 20(1); 164–75. ©2013 AACR.

[1]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[2]  D. Sargent,et al.  Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. , 2012, JAMA.

[3]  M. Salto‐Tellez,et al.  Lgr5 expression is absent in human premalignant lesions of the stomach , 2012, Gut.

[4]  Hui Gao,et al.  Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy , 2011, International journal of cancer.

[5]  Chien-Hsing Lee,et al.  Axl Is a Prognostic Marker in Oral Squamous Cell Carcinoma , 2012, Annals of Surgical Oncology.

[6]  Sridhar Ramaswamy,et al.  Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Salto‐Tellez,et al.  KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma , 2011, Cytopathology : official journal of the British Society for Clinical Cytology.

[8]  Li Lin,et al.  STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. , 2011, Cancer research.

[9]  Chih-Yang Huang,et al.  CD133/Src Axis Mediates Tumor Initiating Property and Epithelial-Mesenchymal Transition of Head and Neck Cancer , 2011, PloS one.

[10]  S. Liyanarachchi,et al.  Glioma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. , 2011, Neoplasia.

[11]  Sharmila Shankar,et al.  Targeting Epigenetic Regulation of miR-34a for Treatment of Pancreatic Cancer by Inhibition of Pancreatic Cancer Stem Cells , 2011, PloS one.

[12]  M. Salto‐Tellez,et al.  Sequential expression of putative stem cell markers in gastric carcinogenesis , 2011, British Journal of Cancer.

[13]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[14]  Shuji Ogino,et al.  STAT3 Expression, Molecular Features, Inflammation Patterns, and Prognosis in a Database of 724 Colorectal Cancers , 2011, Clinical Cancer Research.

[15]  P. Johnston,et al.  Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. , 2011, Cancer research.

[16]  Dennis B. Troup,et al.  NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..

[17]  N. Petrelli,et al.  Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. V. van't Veer,et al.  Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Stuart Thomson,et al.  A systems view of epithelial–mesenchymal transition signaling states , 2010, Clinical & Experimental Metastasis.

[20]  E. Montgomery,et al.  The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma , 2010, Cancer biology & therapy.

[21]  H. Earp,et al.  Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors , 2010, Expert opinion on therapeutic targets.

[22]  P. Johnston,et al.  Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer , 2010, Clinical Cancer Research.

[23]  M. Todaro,et al.  Colon cancer stem cells: promise of targeted therapy. , 2010, Gastroenterology.

[24]  T. Yeatman,et al.  Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. , 2010, Gastroenterology.

[25]  Y. Hitoshi,et al.  R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. , 2010, Cancer research.

[26]  M. Salto‐Tellez,et al.  CD133 expression predicts for non-response to chemotherapy in colorectal cancer , 2010, Modern Pathology.

[27]  Bjørn Tore Gjertsen,et al.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.

[28]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[29]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[30]  P. Johnston,et al.  Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL. , 2008, Cancer research.

[31]  Ming-Tseh Lin,et al.  Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. , 2008, Cancer letters.

[32]  Stuart Thomson,et al.  Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy , 2008, Clinical & Experimental Metastasis.

[33]  H. Earp,et al.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. , 2008, Advances in cancer research.

[34]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  David M. Thomas,et al.  High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer , 2006, BMC Cancer.

[36]  B. Dahlbäck,et al.  Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. , 2006, Cytokine & growth factor reviews.

[37]  M. Essig,et al.  Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Y. Chu,et al.  Expression of axl in lung adenocarcinoma and correlation with tumor progression. , 2005, Neoplasia.

[39]  T. Wilson,et al.  Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP , 2005, Molecular Cancer Therapeutics.

[40]  P. Johnston.  Stage II colorectal cancer: to treat or not to treat. , 2005, The oncologist.

[41]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[42]  M. Meyers,et al.  Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. , 2001, Cancer research.

[43]  M. Salgaller.  American Association for Cancer Research , 2000, Expert opinion on investigational drugs.

[44]  E. Ruaro,et al.  Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras , 1999, Oncogene.

[45]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[46]  C. Basilico,et al.  The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding , 1995, Molecular and cellular biology.

[47]  J. Izbicki,et al.  Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. , 1993, Journal of the National Cancer Institute.

[48]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[49]  A. Schulz,et al.  A novel putative tyrosine kinase receptor with oncogenic potential. , 1991, Oncogene.

[50]  R. Espinosa,et al.  axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase , 1991, Molecular and cellular biology.